The effect of angiotensin receptor blockade alone or in combination with spironolactone on the process of ventricular remodeling in chronic heart failure.

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-09000648

Enrollment

Unknown

Registered

2005-09-09

Start date

2001-10-08

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart and Blood Vessel Diseases

Interventions

Two groups:Candesartan + Spirolactone verus Candesartan + Placebo, one year

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: Inclusion criteria *Typical features of congestive heart failure. *LVEF < 40%.

Exclusion criteria

Exclusion criteria: Exclusion criteria *Patients with renal failure, serum creatinine > 200 mmol/ltr. *Other major serious medical conditions such as malignancy, liver failure, uncontrolled diabetes. Gender and age will be balanced in the two randomized groups.

Design outcomes

Primary

Measure	Time frame
We sought to determine the beneficial effect of candesartan alone or in combination with spironolactone on left ventricular remodelling;	—

Countries

China

Contacts

Public ContactProf. John E. Sanderson

www.na@163.com+852 37636050

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026